
BNP Paribas Exane upgraded Covivio (EPA:COV) to Outperform from Neutral, raising its price target to EUR64.00 from EUR52.00. This upgrade follows Covivio's recent interim results, prompting the firm to increase its FY25 and FY26 earnings forecasts by 4% and 5% respectively. The positive outlook is primarily attributed to Covivio's favorable portfolio rebalancing strategy, which is expected to drive earnings growth and total returns, with the stock's valuation remaining attractive despite its year-to-date outperformance.
BNP Paribas Exane has upgraded Covivio (EPA:COV) to Outperform from a Neutral rating, concurrently raising its price target to EUR64.00 from EUR52.00. This revision is a direct response to Covivio's recent interim financial results, which prompted the research firm to increase its earnings forecasts for fiscal years 2025 and 2026 by 4% and 5%, respectively. The core thesis for the upgrade rests on a favorable assessment of Covivio's portfolio rebalancing strategy, which is anticipated to be a key driver of future earnings growth and total shareholder returns. Notably, despite the stock's outperformance year-to-date, BNP Paribas Exane asserts that Covivio's valuation remains attractive. The firm's positive outlook persists even while acknowledging that the strategy will necessitate significant volumes of capital recycling to achieve the desired portfolio composition.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment